Emmaus Medical   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Torrance CA United States (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
2003
NCT00586209
First Marketed Drug
2004
l-glutamine
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CEO, Emmaus Medical, Inc | EMMAUS MEDCL | Emmaus Medical, Inc.

Active Ingredients

Marketed Drugs (1)

l-glutamine (2004)

Drugs in Phase 4 Trials (1)

l-glutamine (8 trials)

Drugs in Phase 3 Trials (1)

maltodextrin (1 trial)

Drugs in Phase 2 Trials (1)

l-alanine (2 trials)

Drugs in Phase 1 Trials (2)

gemcitabine (gemzar) (1 trial)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Anemia (Phase 3)

Anemia, Sickle Cell (Phase 4)

Cystic Fibrosis (Phase 2)

Fibrosis (Phase 2)

Pancreatic Neoplasms (Phase 1)

Thalassemia (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 5